Literature DB >> 19403674

Nuclear-cytoplasmic shuttling is not required for the Epstein-Barr virus EBNA-LP transcriptional coactivation function.

Paul D Ling1, Jie Tan, RongSheng Peng.   

Abstract

Epstein-Barr virus (EBV) EBNA-LP is a transcriptional coactivator of EBNA2 that works though interaction with the promyelocytic leukemia nuclear-body-associated protein Sp100A. EBNA-LP localizes predominantly in the nucleus through the action of nuclear localization signals in the repeated regions of the protein. EBNA-LP has also been detected in the cytoplasm, and a previous study suggested that some of the EBNA-LP coactivation function is mediated by relocalizing histone deacetylase 4 (HDAC4) from the nucleus to the cytoplasm. Although EBNA-LP can be found in the cytoplasm, it has no obvious nuclear export signal, and there is no direct evidence for active shuttling between these cellular compartments. Whether active shuttling between the nucleus and cytoplasm is required for coactivation remains to be clarified. To address these issues, we tested a variety of EBNA-LP isoforms and mutants for nuclear-cytoplasmic shuttling activity in an interspecies heterokaryon assay and for the ability to associate with HDAC4. EBNA-LP isoforms smaller than 42 kDa shuttle efficiently in the heterokaryon assay via a crm-1-independent mechanism. In addition, no specific EBNA-LP domain that mediates nuclear export could be identified. In contrast, an EBNA-LP 62-kDa isoform does not demonstrate detectable shuttling in the heterokaryon assay yet still coactivates EBNA2 similarly to the smaller EBNA-LP isoforms. All of the EBNA-LP mutants tested, including the coactivation-deficient DeltaCR3 mutant and the nonshuttling 62-kDa isoform, were capable of associating with HDAC4. Taken together, our results suggest that simple diffusion may account for the nuclear export observed with smaller isoforms of EBNA-LP, that nuclear-cytoplasmic shuttling is not required for efficient EBNA-LP coactivation function, and that competence for HDAC4 association is not sufficient to mediate nuclear-cytoplasmic shuttling or EBNA-LP coactivation in the absence of a functional interaction with Sp100A.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403674      PMCID: PMC2704764          DOI: 10.1128/JVI.00654-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function.

Authors:  Eamon M McCann; Gemma L Kelly; Alan B Rickinson; Andrew I Bell
Journal:  J Gen Virol       Date:  2001-12       Impact factor: 3.891

Review 2.  Transport into and out of the nucleus.

Authors:  I G Macara
Journal:  Microbiol Mol Biol Rev       Date:  2001-12       Impact factor: 11.056

3.  Epstein-Barr virus nuclear antigen 5 interacts with HAX-1, a possible component of the B-cell receptor signalling pathway.

Authors:  Martin Dufva; Maria Olsson; Lars Rymo
Journal:  J Gen Virol       Date:  2001-07       Impact factor: 3.891

4.  Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.

Authors:  R Peng; J Tan; P D Ling
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Interaction of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: implication of cytoplasmic function of EBNA-LP.

Authors:  Y Kawaguchi; K Nakajima; M Igarashi; T Morita; M Tanaka; M Suzuki; A Yokoyama; G Matsuda; K Kato; M Kanamori; K Hirai
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 6.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  The modular nature of histone deacetylase HDAC4 confers phosphorylation-dependent intracellular trafficking.

Authors:  X Zhao; A Ito; C D Kane; T S Liao; T A Bolger; S M Lemrow; A R Means; T P Yao
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

8.  Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus.

Authors:  A V Gordadze; R Peng; J Tan; G Liu; R Sutton; B Kempkes; G W Bornkamm; P D Ling
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Histone deacetylase 4 possesses intrinsic nuclear import and export signals.

Authors:  A H Wang; X J Yang
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

10.  Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) forms complexes with a cellular anti-apoptosis protein Bcl-2 or its EBV counterpart BHRF1 through HS1-associated protein X-1.

Authors:  Go Matsuda; Kaori Nakajima; Yasushi Kawaguchi; Yuji Yamanashi; Kanji Hirai
Journal:  Microbiol Immunol       Date:  2003       Impact factor: 1.955

View more
  4 in total

1.  The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.

Authors:  Maria Takacs; Judit Segesdi; Ferenc Banati; Anita Koroknai; Hans Wolf; Hans Helmut Niller; Janos Minarovits
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-11-15       Impact factor: 2.576

2.  Heterokaryon technique for analysis of cell type-specific localization.

Authors:  Roseann Gammal; Krista Baker; Destin Heilman
Journal:  J Vis Exp       Date:  2011-03-11       Impact factor: 1.355

3.  New Interactors of the Truncated EBNA-LP Protein Identified by Mass Spectrometry in P3HR1 Burkitt's Lymphoma Cells.

Authors:  Sonia Chelouah; Emilie Cochet; Sophie Couvé; Sandy Balkaran; Aude Robert; Evelyne May; Vasily Ogryzko; Joëlle Wiels
Journal:  Cancers (Basel)       Date:  2018-01-05       Impact factor: 6.639

4.  Heterogeneity of the Epstein-Barr Virus (EBV) Major Internal Repeat Reveals Evolutionary Mechanisms of EBV and a Functional Defect in the Prototype EBV Strain B95-8.

Authors:  Mohammed M Ba Abdullah; Richard D Palermo; Anne L Palser; Nicholas E Grayson; Paul Kellam; Samantha Correia; Agnieszka Szymula; Robert E White
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.